In this study, we explored whether repurposed metabolic drugs could influence AD pathology using the 5xFAD mouse model, a well-established and aggressive amyloidogenic transgenic line that expresses mutant forms of human APP and PSEN1. The gene discussed is APP; the disease is Alzheimer disease.